Drug Trial Radar · NCT05508906
Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer
Last checked: Nov 19, 2026Latest source record: Sep 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
190
Planned (sponsor's estimate)
Start
Aug 31, 2022
Primary completion
Dec 31, 2027
Study completion Jan 31, 2028
Sponsor
- Lead sponsor
- Olema Oncology, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Novartis; Pfizer
- First posted
- Aug 19, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1b open-label, 2-part study in 4 treatment groups. The 4 treatment groups are as follows: Treatment Group 1: Palazestrant (OP-1250) in combination with ribociclib (KISQALI®, Novartis Pharmaceuticals Corporation). Treatment Group 2: Palazestrant (OP-1250) in combination with alpelisib (PIQRAY®, Novartis Pharmaceuticals Corporation). Treatment Group 3: Palazestrant (OP-1250) in combination with everolimus. Treatment Group 4: Palazestrant (OP-1250) in combination with atirmociclib.
Conditions
- Metastatic Breast Cancer
- ER-positive Breast Cancer
- HER2-negative Breast Cancer
- Breast Cancer
- Locally Advanced Breast Cancer
Interventions
PalazestrantDrug
Complete estrogen receptor antagonist (CERAN)
RibociclibDrug
All subjects in Treatment Group 1 will receive palazestrant in combination with ribociclib.
AlpelisibDrug
All subjects in Treatment Group 2 will receive palazestrant in combination with alpelisib.
EverolimusDrug
All subjects in Treatment Group 3 will receive palazestrant in combination with everolimus.
AtirmociclibDrug
All subjects in Treatment Group 4 will receive palazestrant in combination with atirmociclib.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose Limiting Toxicities (DLTs)Time frame: The first 28 days of treatment
- Characterize the incidence, nature and severity of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs) of palazestrant when administered with ribociclib, alpelisib, everolimus, or atirmociclib.Time frame: Up to 30 days after last dose of study drug(s) treatment
- Pharmacokinetics (PK) of palazestrant when administered with ribociclib (Treatment Group 1) or alpelisib (Treatment Group 2), everolimus (Treatment Group 3), or atirmociclib (Treatment Group 4) .Time frame: Every 28 days
Locations
16 sites in 2 countries. Site status is shown where the registry gives one.
Banner MD Anderson Cancer Center
Gilbert, Arizona
University of California San Francisco Health
San Francisco, California
University of Colorado Cancer Center
Aurora, Colorado
Advent Health Hematology and Oncology
Orlando, Florida
University of Iowa
Iowa City, Iowa
Dana Farber Cancer Institute
Boston, Massachusetts
Henry Ford Health
Detroit, Michigan
Regents of the University of Minnesota
Minneapolis, Minnesota
Washington University, School of Medicine
St Louis, Missouri
Ichan School of Medicine at Mount Sinai
New York, New York
Atrium Health Levine Cancer Institute
Charlotte, North Carolina
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee
MD Anderson Cancer Center
Houston, Texas
Northwest Medical Specialties
Tacoma, Washington
Macquarie Health
Sydney, New South Wales, Australia
Breast Cancer Research Center- Western Australia
Nedlands, Western Australia, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.